Based on 15 Wall Street analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $50.20 with a high forecast of $83.00 and a low forecast of $24.00. The average price target represents a 18.56% change from the last price of $42.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Proxima_Nova_regular","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","60":"$60","97":"$97","41.5":"$41.5","78.5":"$78.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":83,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$83.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.2,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$50.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.5,60,78.5,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Sep<br/>2023","25":"Sep<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.75,41.23076923076923,44.71153846153846,48.19230769230769,51.67307692307692,55.15384615384615,58.63461538461539,62.11538461538461,65.59615384615384,69.07692307692308,72.5576923076923,76.03846153846155,79.51923076923077,{"y":83,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.75,38.707692307692305,39.66538461538462,40.62307692307692,41.580769230769235,42.53846153846154,43.496153846153845,44.45384615384616,45.41153846153846,46.36923076923077,47.32692307692308,48.284615384615385,49.2423076923077,{"y":50.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.75,36.69230769230769,35.63461538461539,34.57692307692308,33.51923076923077,32.46153846153846,31.403846153846153,30.346153846153847,29.28846153846154,28.23076923076923,27.173076923076923,26.115384615384613,25.057692307692307,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.18,"date":1663891200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.89,"date":1665100800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.14,"date":1667520000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.25,"date":1669939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.84,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.57,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.31,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.46,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.96,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.26,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.46,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$83.00

Average Price Target$50.20

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Reiterated

2023-09-13

xxxxxxxxxxxxxxxxxx

Scotiabank

xxxxxxxxxxxxx

Assigned

2023-09-11

xxxxxxxxxxxxxxxxxx

JMP Securities

xxxxxxxxxxxxx

Reiterated

2023-09-11

xxxxxxxxxxxxxxxxxx

JonesTrading

xxxxxxxxxxxxx

Assigned

2023-09-10

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

2023-09-06

xxxxxxxxxxxxxxxxxx

B.Riley Financial

xxxxxxxxxxxxx

Reiterated

2023-08-14

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

2023-08-09

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Upgraded

2023-08-09

xxxxxxxxxxxxxxxxxx

BMO Capital

xxxxxxxxxxxxx

Reiterated

2023-08-09

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

2023-08-09

Michael Ulz

Morgan Stanley

$37.00

Hold

-12.61%

Downside

Reiterated

2023-08-09

Mirati Therapeutics (MRTX) PT Lowered to $37 at Morgan StanleyMorgan Stanley analyst Michael Ulz lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $37.00 (from $42.00) while maintaining a Equalweight rating.

Joseph Catanzaro

Piper Sandler

$45.00

Buy

6.28%

Upside

Assigned

2023-08-09

Piper Sandler Keeps Their Buy Rating on Mirati Therapeutics (MRTX)

Jason Gerberry

Bank of America Securities

$45.00

Hold

6.28%

Upside

Reiterated

2023-08-09

Bank of America Securities Sticks to Their Hold Rating for Mirati Therapeutics (MRTX)

Benjamin Burnett

Stifel Nicolaus

$83.00

Buy

96.03%

Upside

Reiterated

2023-08-09

Mirati Therapeutics price target raised to $83 from $77 at StifelMirati Therapeutics price target raised to $83 from $77 at Stifel

Michael Schmidt

Guggenheim

$60.00

Buy

41.71%

Upside

Reiterated

2023-07-24

Mirati Therapeutics price target lowered to $60 from $104 at GuggenheimMirati Therapeutics price target lowered to $60 from $104 at Guggenheim

Best Analysts Covering Mirati Therapeutics

Which Analyst Should I Follow If I Want to Buy MRTX and Sell After:

1 Month

Jay OlsonOppenheimer

Success Rate

9/17 ratings generated profit

Average Return

+1.42%

reiterated a buy rating 14 days ago

Copying Jay Olson's trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +1.42% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Jay OlsonOppenheimer

Success Rate

10/17 ratings generated profit

Average Return

+13.04%

reiterated a buy rating 14 days ago

Copying Jay Olson's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +13.04% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Jay OlsonOppenheimer

Success Rate

10/17 ratings generated profit

Average Return

+29.89%

reiterated a buy rating 14 days ago

Copying Jay Olson's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +29.89% per trade.

2 Years

Jay OlsonOppenheimer

Success Rate

10/17 ratings generated profit

Average Return

+39.22%

reiterated a buy rating 14 days ago

Copying Jay Olson's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +39.22% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MRTX Financial Forecast

MRTX Earnings Forecast

Next quarter’s earnings estimate for MRTX is -$2.83 with a range of -$3.34 to -$1.89. The previous quarter’s EPS was -$3.04. MRTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.63% of the time in the same period. In the last calendar year MRTX has Outperformed its overall industry.

MRTX Sales Forecast

Next quarter’s sales forecast for MRTX is $19.38M with a range of $15.35M to $28.90M. The previous quarter’s sales results were $13.69M. MRTX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 44.67% of the time in the same period. In the last calendar year MRTX has Outperformed its overall industry.

MRTX Analyst Recommendation Trends

In the current month, MRTX has received 4 Buy ratings 0 Hold ratings, and 1 Sell ratings. The MRTX average analyst price target in the past 3 months is $50.20

MRTX Stock Forecast FAQ

What is MRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirati Therapeutics’s 12-month average price target is $50.20.

What is MRTX’s upside potential, based on the analysts’ average price target?

Mirati Therapeutics has 18.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRTX a Buy, Sell or Hold?

Mirati Therapeutics has a conensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 1 sell ratings.

What is Mirati Therapeutics’s price target?

The average price target for Mirati Therapeutics is $50.20. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $83.00 ,the lowest forecast is $24.00. The average price target represents 18.56% Increase from the current price of $42.34.

What do analysts say about Mirati Therapeutics?

Mirati Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of MRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mirati Therapeutics (MRTX) Stock Forecast & Price Target

MRTX Analyst Ratings

MRTX Stock 12 Months Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirati Therapeutics

MRTX Financial Forecast

MRTX Earnings Forecast

MRTX Sales Forecast

MRTX Analyst Recommendation Trends

MRTX Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts